[{"id":"1c9d80ce-106c-469a-99e8-5c3c73aed1a7","acronym":"SARCLUNG","url":"https://clinicaltrials.gov/study/NCT06808113","created_at":"2025-02-25T16:49:17.593Z","updated_at":"2025-02-25T16:49:17.593Z","phase":"","brief_title":"Circulating and Molecular Markers Involved in the Processes of Cachexia, Anorexia and Sarcopenia in Patients With NSCLC","source_id_and_acronym":"NCT06808113 - SARCLUNG","lead_sponsor":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","biomarkers":" GDF15 • FGF21","pipe":"","alterations":" ","tags":["GDF15 • FGF21"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 11/07/2022","start_date":" 11/07/2022","primary_txt":" Primary completion: 10/07/2024","primary_completion_date":" 10/07/2024","study_txt":" Completion: 08/01/2027","study_completion_date":" 08/01/2027","last_update_posted":"2025-02-05"},{"id":"b5db1fc8-e9fe-4d5e-bf2f-a03d1a7ecfab","acronym":"PROACC-1","url":"https://clinicaltrials.gov/study/NCT05546476","created_at":"2022-09-19T13:55:53.529Z","updated_at":"2025-02-25T17:02:09.889Z","phase":"Phase 2","brief_title":"Study of the Efficacy and Safety of Ponsegromab in Patients With Cancer, Cachexia and Elevated GDF-15","source_id_and_acronym":"NCT05546476 - PROACC-1","lead_sponsor":"Pfizer","biomarkers":" GDF15","pipe":"","alterations":" ","tags":["GDF15"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ponsegromab (PF-06946860)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 187","initiation":"Initiation: 11/21/2022","start_date":" 11/21/2022","primary_txt":" Primary completion: 03/13/2024","primary_completion_date":" 03/13/2024","study_txt":" Completion: 04/21/2025","study_completion_date":" 04/21/2025","last_update_posted":"2025-02-03"},{"id":"9cbf2f0f-79e3-4928-a4ed-5ed00dfa5bc5","acronym":"","url":"https://clinicaltrials.gov/study/NCT06713993","created_at":"2025-02-26T10:41:48.420Z","updated_at":"2025-02-26T10:41:48.420Z","phase":"","brief_title":"Semmelweis Esophageal Cancer Study: Noninvasive Prognostic Parameters in Patients With Oesophageal and Esophagogastric Junction Cancer","source_id_and_acronym":"NCT06713993","lead_sponsor":"Semmelweis University","biomarkers":" IL6 • GDF15 • IGF1","pipe":"","alterations":" ","tags":["IL6 • GDF15 • IGF1"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 09/10/2024","start_date":" 09/10/2024","primary_txt":" Primary completion: 09/30/2029","primary_completion_date":" 09/30/2029","study_txt":" Completion: 09/10/2034","study_completion_date":" 09/10/2034","last_update_posted":"2024-12-03"},{"id":"9ce1ae1c-3677-40b4-81f0-ce916a71323c","acronym":"","url":"https://clinicaltrials.gov/study/NCT02633059","created_at":"2025-09-06T20:42:42.259Z","updated_at":"2025-09-06T20:42:42.259Z","phase":"Phase 1/2","brief_title":"Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma","source_id_and_acronym":"NCT02633059","lead_sponsor":"Mayo Clinic","biomarkers":" GDF15","pipe":"","alterations":" ","tags":["GDF15"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ninlaro (ixazomib) • idasanutlin (RG7388)"],"overall_status":"Completed","enrollment":" Enrollment 33","initiation":"Initiation: 12/30/2015","start_date":" 12/30/2015","primary_txt":" Primary completion: 01/31/2021","primary_completion_date":" 01/31/2021","study_txt":" Completion: 11/01/2022","study_completion_date":" 11/01/2022","last_update_posted":"2024-09-12"},{"id":"94d853f9-4b00-4d0a-bff5-5b95c63b63ef","acronym":"","url":"https://clinicaltrials.gov/study/NCT04824053","created_at":"2021-04-01T17:52:24.857Z","updated_at":"2024-07-02T16:34:27.500Z","phase":"","brief_title":"Effects of UNICLA-A2 Dairy Products on Patients at High-risk of Colorectal Cancer Development","source_id_and_acronym":"NCT04824053","lead_sponsor":"Instituto de Investigación Sanitaria Aragón","biomarkers":" IL6 • TNFA • GDF15 • CRP","pipe":"","alterations":" ","tags":["IL6 • TNFA • GDF15 • CRP"],"overall_status":"Recruiting","enrollment":" Enrollment 34","initiation":"Initiation: 02/28/2022","start_date":" 02/28/2022","primary_txt":" Primary completion: 05/30/2025","primary_completion_date":" 05/30/2025","study_txt":" Completion: 02/15/2026","study_completion_date":" 02/15/2026","last_update_posted":"2024-06-11"},{"id":"202ef95b-6ce3-4ba1-a775-99a544ce6adc","acronym":"SaVe","url":"https://clinicaltrials.gov/study/NCT05710809","created_at":"2024-04-19T19:53:03.304Z","updated_at":"2024-07-02T16:35:08.672Z","phase":"","brief_title":"The SaVe Project-Sarcopenia and Vertigo in Aging Patients With Colorectal Cancer","source_id_and_acronym":"NCT05710809 - SaVe","lead_sponsor":"Rigshospitalet, Denmark","biomarkers":" IL6 • GDF15 • CRP","pipe":"","alterations":" ","tags":["IL6 • GDF15 • CRP"],"overall_status":"Recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 02/20/2023","start_date":" 02/20/2023","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 09/01/2026","study_completion_date":" 09/01/2026","last_update_posted":"2024-04-19"},{"id":"8626d796-d31d-4f11-a4ab-8ea3dce4cf77","acronym":"","url":"https://clinicaltrials.gov/study/NCT03725436","created_at":"2021-01-18T18:15:21.875Z","updated_at":"2024-07-02T16:35:08.781Z","phase":"Phase 1","brief_title":"ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors","source_id_and_acronym":"NCT03725436","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HER-2 • ER • TP53 • MDM2 • MDM4 • GDF15 • CASP3 • CDKN1A","pipe":" | ","alterations":" ER positive • HER-2 negative • TP53 wild-type • MDM4 amplification • MDM2 mutation • TP53 amplification","tags":["HER-2 • ER • TP53 • MDM2 • MDM4 • GDF15 • CASP3 • CDKN1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • TP53 wild-type • MDM4 amplification • MDM2 mutation • TP53 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • sulanemadlin (ALRN-6924)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 01/24/2019","start_date":" 01/24/2019","primary_txt":" Primary completion: 04/30/2025","primary_completion_date":" 04/30/2025","study_txt":" Completion: 04/30/2025","study_completion_date":" 04/30/2025","last_update_posted":"2024-04-18"},{"id":"f3010772-e6aa-4176-a889-5f0ef649517e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04361240","created_at":"2021-01-18T21:04:58.701Z","updated_at":"2024-07-02T16:35:10.399Z","phase":"","brief_title":"Cardiotoxicity in Breast Cancer Patients Treated With Proton or Photon Radiotherapy: A RadComp Companion Study","source_id_and_acronym":"NCT04361240","lead_sponsor":"Abramson Cancer Center at Penn Medicine","biomarkers":" GDF15","pipe":"","alterations":" ","tags":["GDF15"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 175","initiation":"Initiation: 08/01/2020","start_date":" 08/01/2020","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 04/01/2025","study_completion_date":" 04/01/2025","last_update_posted":"2024-04-10"},{"id":"f65c4c18-9c0b-417b-be80-3f84d4c413f4","acronym":"","url":"https://clinicaltrials.gov/study/NCT05865535","created_at":"2023-05-19T13:04:39.378Z","updated_at":"2024-07-02T16:35:11.202Z","phase":"Phase 1","brief_title":"A Dose Escalation Study of AV-380 in Metastatic Cancer Patients With Cachexia","source_id_and_acronym":"NCT05865535","lead_sponsor":"AVEO Pharmaceuticals, Inc.","biomarkers":" GDF15","pipe":"","alterations":" ","tags":["GDF15"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 06/13/2023","start_date":" 06/13/2023","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 09/30/2025","study_completion_date":" 09/30/2025","last_update_posted":"2024-04-05"},{"id":"56701609-6e73-415e-9aa3-488dcc9b08a6","acronym":"","url":"https://clinicaltrials.gov/study/NCT03656731","created_at":"2021-01-18T17:56:54.367Z","updated_at":"2024-07-02T16:35:35.128Z","phase":"","brief_title":"Exercise in Older Women With Breast Cancer During Systemic Therapy","source_id_and_acronym":"NCT03656731","lead_sponsor":"Herlev and Gentofte Hospital","biomarkers":" HER-2 • IL6 • GDF15 • CHI3L1 • CRP","pipe":"","alterations":" ","tags":["HER-2 • IL6 • GDF15 • CHI3L1 • CRP"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 11/15/2018","start_date":" 11/15/2018","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2023-10-02"},{"id":"385c9ccf-6d69-4244-a6c5-7b7eda99b732","acronym":"GDFather-NEO","url":"https://clinicaltrials.gov/study/NCT06059547","created_at":"2023-09-28T14:10:37.972Z","updated_at":"2024-07-02T16:35:35.337Z","phase":"Phase 2","brief_title":"Neoadjuvant Immunotherapy in Combination With the Anti-GDF-15 Antibody Visugromab (CTL-002) for Treatment of Muscle Invasive Bladder Cancer","source_id_and_acronym":"NCT06059547 - GDFather-NEO","lead_sponsor":"CatalYm GmbH","biomarkers":" GDF15","pipe":"","alterations":" ","tags":["GDF15"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • visugromab (CTL-002)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 09/06/2023","start_date":" 09/06/2023","primary_txt":" Primary completion: 08/31/2024","primary_completion_date":" 08/31/2024","study_txt":" Completion: 08/31/2025","study_completion_date":" 08/31/2025","last_update_posted":"2023-09-28"},{"id":"b1da365e-a483-4a44-b386-de93bae5a04a","acronym":"CLARITY","url":"https://clinicaltrials.gov/study/NCT04305613","created_at":"2021-01-18T20:52:50.080Z","updated_at":"2024-07-02T16:35:46.742Z","phase":"","brief_title":"Cardiotoxicity in Locally Advanced Lung Cancer Patients Treated With Chemoradiation Therapy","source_id_and_acronym":"NCT04305613 - CLARITY","lead_sponsor":"Abramson Cancer Center at Penn Medicine","biomarkers":" GDF15 • CRP","pipe":"","alterations":" ","tags":["GDF15 • CRP"],"overall_status":"Enrolling by invitation","enrollment":" Enrollment 221","initiation":"Initiation: 09/14/2020","start_date":" 09/14/2020","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/01/2028","study_completion_date":" 09/01/2028","last_update_posted":"2023-05-31"},{"id":"311e337d-e531-43a3-a80a-c059e2c8059b","acronym":"PINNACLES","url":"https://clinicaltrials.gov/study/NCT04068896","created_at":"2022-08-10T15:55:54.899Z","updated_at":"2024-07-02T16:35:49.007Z","phase":"Phase 1/2","brief_title":"Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy","source_id_and_acronym":"NCT04068896 - PINNACLES","lead_sponsor":"NGM Biopharmaceuticals, Inc","biomarkers":" GDF15","pipe":"","alterations":" ","tags":["GDF15"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NGM120"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 75","initiation":"Initiation: 10/16/2019","start_date":" 10/16/2019","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2023-05-04"},{"id":"590d7a7e-a846-470d-83ae-990b856075e9","acronym":"STAY-STRONG","url":"https://clinicaltrials.gov/study/NCT05556239","created_at":"2022-09-27T14:04:38.350Z","updated_at":"2024-07-02T16:35:49.541Z","phase":"","brief_title":"STAY-STRONG Study of Exercise Training During Chemotherapy","source_id_and_acronym":"NCT05556239 - STAY-STRONG","lead_sponsor":"Rigshospitalet, Denmark","biomarkers":" IL6 • TNFA • GDF15 • CRP","pipe":"","alterations":" ","tags":["IL6 • TNFA • GDF15 • CRP"],"overall_status":"Recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 10/25/2022","start_date":" 10/25/2022","primary_txt":" Primary completion: 10/01/2024","primary_completion_date":" 10/01/2024","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2023-04-26"},{"id":"4b575e04-7bcc-46f7-b76b-665b78c28d37","acronym":"GEPOC","url":"https://clinicaltrials.gov/study/NCT03719573","created_at":"2021-01-18T18:13:49.893Z","updated_at":"2024-07-02T16:36:06.178Z","phase":"","brief_title":"Geriatric Assessment and Intervention in Older Patients Undergoing Surgery for Colorectal Cancer","source_id_and_acronym":"NCT03719573 - GEPOC","lead_sponsor":"Herlev and Gentofte Hospital","biomarkers":" IL6 • GDF15 • CHI3L1 • CRP","pipe":"","alterations":" ","tags":["IL6 • GDF15 • CHI3L1 • CRP"],"overall_status":"Completed","enrollment":" Enrollment 67","initiation":"Initiation: 02/21/2019","start_date":" 02/21/2019","primary_txt":" Primary completion: 05/10/2022","primary_completion_date":" 05/10/2022","study_txt":" Completion: 05/10/2022","study_completion_date":" 05/10/2022","last_update_posted":"2022-08-03"},{"id":"f639df2f-b80b-4b0e-9bef-2bba3806e588","acronym":"","url":"https://clinicaltrials.gov/study/NCT02496260","created_at":"2021-01-18T12:02:16.669Z","updated_at":"2024-07-02T16:36:16.063Z","phase":"","brief_title":"Biomarkers and Cardiac MRI as Early Indicators of Cardiac Exposure Following Breast Radiotherapy","source_id_and_acronym":"NCT02496260","lead_sponsor":"Henry Ford Health System","biomarkers":" GDF15 • LGALS3 • CRP • MPO • NPPB","pipe":"","alterations":" ","tags":["GDF15 • LGALS3 • CRP • MPO • NPPB"],"overall_status":"Completed","enrollment":" Enrollment 25","initiation":"Initiation: 07/01/2015","start_date":" 07/01/2015","primary_txt":" Primary completion: 12/01/2017","primary_completion_date":" 12/01/2017","study_txt":" Completion: 12/01/2018","study_completion_date":" 12/01/2018","last_update_posted":"2022-03-03"},{"id":"edf53596-6aa6-468f-8663-c4465c482691","acronym":"","url":"https://clinicaltrials.gov/study/NCT02895178","created_at":"2021-01-18T14:12:21.018Z","updated_at":"2024-07-02T16:36:32.226Z","phase":"","brief_title":"Lifestyles Of Health And Sustainability for Breast Cancer Survivors","source_id_and_acronym":"NCT02895178","lead_sponsor":"Wonju Severance Christian Hospital","biomarkers":" CTNNB1 • TNFA • DKK1 • GDF15 • IL10 • FGF21 • IL1B • SFRP1 • BDNF • TNFRSF11B","pipe":"","alterations":" ","tags":["CTNNB1 • TNFA • DKK1 • GDF15 • IL10 • FGF21 • IL1B • SFRP1 • BDNF • TNFRSF11B"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 05/01/2014","start_date":" 05/01/2014","primary_txt":" Primary completion: 03/01/2023","primary_completion_date":" 03/01/2023","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2021-04-08"},{"id":"a599bd6d-bb48-4886-a056-1c6c4c34af61","acronym":"","url":"https://clinicaltrials.gov/study/NCT02343172","created_at":"2021-01-18T11:08:16.439Z","updated_at":"2024-07-02T16:36:37.589Z","phase":"Phase 1","brief_title":"Study of Safety and Efficacy of HDM201 in Combination With LEE011 in Patients With Liposarcoma","source_id_and_acronym":"NCT02343172","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" CDK4 • GDF15 • CDKN1A","pipe":"","alterations":" ","tags":["CDK4 • GDF15 • CDKN1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kisqali (ribociclib) • siremadlin (HDM201)"],"overall_status":"Completed","enrollment":" Enrollment 74","initiation":"Initiation: 03/13/2015","start_date":" 03/13/2015","primary_txt":" Primary completion: 10/16/2019","primary_completion_date":" 10/16/2019","study_txt":" Completion: 10/16/2019","study_completion_date":" 10/16/2019","last_update_posted":"2020-12-09"},{"id":"613e409a-9659-4396-bba3-22b9a39d0fcd","acronym":"","url":"https://clinicaltrials.gov/study/NCT01877382","created_at":"2021-01-18T08:26:57.296Z","updated_at":"2024-07-02T16:36:37.709Z","phase":"Phase 1","brief_title":"A Phase 1 Multiple Ascending Dose Study of Milademetan in Subjects With Advanced Solid Tumors or Lymphomas","source_id_and_acronym":"NCT01877382","lead_sponsor":"Daiichi Sankyo, Inc.","biomarkers":" TP53 • MDM2 • GDF15","pipe":" | ","alterations":" TP53 mutation • MDM2 amplification • MDM2 overexpression","tags":["TP53 • MDM2 • GDF15"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • MDM2 amplification • MDM2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e milademetan (RAIN-32)"],"overall_status":"Completed","enrollment":" Enrollment 108","initiation":"Initiation: 07/01/2013","start_date":" 07/01/2013","primary_txt":" Primary completion: 10/08/2020","primary_completion_date":" 10/08/2020","study_txt":" Completion: 12/03/2020","study_completion_date":" 12/03/2020","last_update_posted":"2020-12-08"},{"id":"2bf15b4f-9a49-45d6-8256-e8bb3a627793","acronym":"","url":"https://clinicaltrials.gov/study/NCT03598582","created_at":"2021-01-18T17:41:35.717Z","updated_at":"2024-07-02T16:37:08.648Z","phase":"Phase 4","brief_title":"Biological Predictive Factors of Response to ESA in Low Risk MDS Patients","source_id_and_acronym":"NCT03598582","lead_sponsor":"Association pour la recherche sur les Affections Malignes en Immunologie Sanguine","biomarkers":" CD34 • GDF15 • CD36 • TFRC","pipe":"","alterations":" ","tags":["CD34 • GDF15 • CD36 • TFRC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Retacrit (epoetin alfa-epbx)"],"overall_status":"Completed","enrollment":" Enrollment 70","initiation":"Initiation: 01/01/2013","start_date":" 01/01/2013","primary_txt":" Primary completion: 05/01/2017","primary_completion_date":" 05/01/2017","study_txt":" Completion: 05/01/2018","study_completion_date":" 05/01/2018","last_update_posted":"2018-07-26"},{"id":"5fdf4cec-8c24-426c-b0fb-4a851eb51a26","acronym":"","url":"https://clinicaltrials.gov/study/NCT02098967","created_at":"2021-01-18T09:41:28.884Z","updated_at":"2024-07-02T16:37:10.664Z","phase":"Phase 1","brief_title":"A Study of the Safety and Pharmacokinetics of RO6839921, An MDM2 Antagonist, in Patients With Advanced Cancers, Including Acute Myeloid Leukemia.","source_id_and_acronym":"NCT02098967","lead_sponsor":"Hoffmann-La Roche","biomarkers":" GDF15","pipe":"","alterations":" ","tags":["GDF15"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RG7775"],"overall_status":"Completed","enrollment":" Enrollment 68","initiation":"Initiation: 04/21/2014","start_date":" 04/21/2014","primary_txt":" Primary completion: 05/07/2018","primary_completion_date":" 05/07/2018","study_txt":" Completion: 05/07/2018","study_completion_date":" 05/07/2018","last_update_posted":"2018-05-17"},{"id":"21fcb4a3-2428-4756-bda3-81d1398926ef","acronym":"","url":"https://clinicaltrials.gov/study/NCT01773408","created_at":"2021-01-18T07:49:00.137Z","updated_at":"2024-07-02T16:37:26.234Z","phase":"Phase 1","brief_title":"A Study of RO5503781 as a Single Agent or in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia","source_id_and_acronym":"NCT01773408","lead_sponsor":"Hoffmann-La Roche","biomarkers":" TP53 • GDF15","pipe":" | ","alterations":" TP53 mutation","tags":["TP53 • GDF15"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • daunorubicin • idarubicin hydrochloride • idasanutlin (RG7388)"],"overall_status":"Completed","enrollment":" Enrollment 122","initiation":"Initiation: 02/01/2013","start_date":" 02/01/2013","primary_txt":" Primary completion: 06/01/2016","primary_completion_date":" 06/01/2016","study_txt":" Completion: 06/01/2016","study_completion_date":" 06/01/2016","last_update_posted":"2017-01-25"},{"id":"68437971-9714-4d65-858d-5223d19a23aa","acronym":"","url":"https://clinicaltrials.gov/study/NCT01462175","created_at":"2021-01-18T06:04:54.371Z","updated_at":"2024-07-02T16:37:27.822Z","phase":"Phase 1","brief_title":"A First-In-Human Study of RO5503781 in Participants With Advanced Malignancies Except Leukemia","source_id_and_acronym":"NCT01462175","lead_sponsor":"Hoffmann-La Roche","biomarkers":" TP53 • MDM2 • GDF15 • CDKN1A","pipe":" | ","alterations":" TP53 mutation","tags":["TP53 • MDM2 • GDF15 • CDKN1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e idasanutlin (RG7388)"],"overall_status":"Completed","enrollment":" Enrollment 99","initiation":"Initiation: 11/01/2011","start_date":" 11/01/2011","primary_txt":" Primary completion: 07/01/2014","primary_completion_date":" 07/01/2014","study_txt":" Completion: 07/01/2014","study_completion_date":" 07/01/2014","last_update_posted":"2016-11-02"},{"id":"869d4b1c-639c-41c3-8658-c66b539f27d4","acronym":"","url":"https://clinicaltrials.gov/study/NCT01635296","created_at":"2021-01-18T07:01:44.816Z","updated_at":"2024-07-02T16:37:27.996Z","phase":"Phase 1b","brief_title":"A Study of RO5045337 in Combination With Cytarabine in Patients With Acute Myelogenous Leukemia","source_id_and_acronym":"NCT01635296","lead_sponsor":"Hoffmann-La Roche","biomarkers":" GDF15","pipe":"","alterations":" ","tags":["GDF15"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • RG7112"],"overall_status":"Completed","enrollment":" Enrollment 43","initiation":"Initiation: 07/01/2012","start_date":" 07/01/2012","primary_txt":" Primary completion: 10/01/2013","primary_completion_date":" 10/01/2013","study_txt":" Completion: 10/01/2013","study_completion_date":" 10/01/2013","last_update_posted":"2016-11-02"}]